Former National Coordinator for Health Information Technology joins PGxAI’s advisory team
Team News | Published: Aug 3, 2025
PGxAI is honored to welcome David Blumenthal, Former National Coordinator for Health Information Technology, Joins PGxAI as a Scientific Advisor.
David Blumenthal is a nationally recognized physician and health policy expert with a career spanning academic medicine, government leadership, and healthcare innovation. He served as the National Coordinator for Health Information Technology under President Obama from 2009 to 2011, where he led one of the largest public infrastructure initiatives in U.S. history-overseeing the implementation of the HITECH Act’s "meaningful use" incentives to digitize American healthcare.
Dr. Blumenthal earned his BA, MD, and MPP from Harvard University, completed his residency at Massachusetts General Hospital, and held academic roles across Harvard Medical School, the Kennedy School of Government, and the Harvard School of Public Health.
Over four decades, he has combined front-line medical practice with influential policy work. He was Chief Health Advisor to Governor Michael Dukakis during his presidential campaign (1987-88) and later to President Obama’s 2008 campaign. In academia, he served as Director of the Institute for Health Policy at MGH and National Correspondent for the New England Journal of Medicine, contributing thought leadership on health systems reform.
His contributions earned him the title of Modern Healthcare’s Most Influential Physician Executive in 2010. Blumenthal is widely respected for bridging clinical insight with visionary policy design in U.S. healthcare.
We are delighted to welcome Dr. David Blumenthal to PGxAI and look forward to his guidance as we continue to transform precision medicine.
About PGxAI
Founded in 2023 and backed by venture capital firm ATEM Capital, PGxAI is at the forefront of AI-driven precision medicine, combining real-world clinical data with advanced genomics research. The company’s proprietary AI platform personalizes drug selection, dosing, and interaction management based on each patient’s unique genetic makeup. Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, serves as CEO & co-founder, alongside Allan Gobbs, a life sciences investor and executive chairman. PGxAI’s advisory board features experts from Stanford University, Thermo Fisher, and GE Healthcare. By partnering with InterSystems and leveraging cutting-edge cloud and HPC technology from leading providers, PGxAI addresses one of healthcare’s most critical needs: ensuring safe and effective treatments for every individual.
